141 related articles for article (PubMed ID: 16178762)
1. New insights in the mechanism of bone loss in arthritis.
Schett G; Smolen JS
Curr Pharm Des; 2005; 11(23):3039-49. PubMed ID: 16178762
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis: inflammation and bone loss.
Schett G
Wien Med Wochenschr; 2006 Jan; 156(1-2):34-41. PubMed ID: 16465612
[TBL] [Abstract][Full Text] [Related]
3. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
4. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance.
Lubberts E; van den Bersselaar L; Oppers-Walgreen B; Schwarzenberger P; Coenen-de Roo CJ; Kolls JK; Joosten LA; van den Berg WB
J Immunol; 2003 Mar; 170(5):2655-62. PubMed ID: 12594294
[TBL] [Abstract][Full Text] [Related]
5. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB
Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250
[TBL] [Abstract][Full Text] [Related]
6. Bone destruction in arthritis.
Gravallese EM
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii84-6. PubMed ID: 12379632
[TBL] [Abstract][Full Text] [Related]
7. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
8. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.
Koenders MI; Lubberts E; Oppers-Walgreen B; van den Bersselaar L; Helsen MM; Di Padova FE; Boots AM; Gram H; Joosten LA; van den Berg WB
Am J Pathol; 2005 Jul; 167(1):141-9. PubMed ID: 15972960
[TBL] [Abstract][Full Text] [Related]
9. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
10. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
11. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
Romas E
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
[TBL] [Abstract][Full Text] [Related]
12. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Gravallese EM; Manning C; Tsay A; Naito A; Pan C; Amento E; Goldring SR
Arthritis Rheum; 2000 Feb; 43(2):250-8. PubMed ID: 10693863
[TBL] [Abstract][Full Text] [Related]
13. Erosive arthritis.
Schett G
Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S2. PubMed ID: 17634141
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Disease: the link between RANKL and arthritic bone disease.
Schett G; Hayer S; Zwerina J; Redlich K; Smolen JS
Nat Clin Pract Rheumatol; 2005 Nov; 1(1):47-54. PubMed ID: 16932627
[TBL] [Abstract][Full Text] [Related]
15. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
16. RANK, RANKL and osteoprotegerin in arthritic bone loss.
Bezerra MC; Carvalho JF; Prokopowitsch AS; Pereira RM
Braz J Med Biol Res; 2005 Feb; 38(2):161-70. PubMed ID: 15785827
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
Herrak P; Görtz B; Hayer S; Redlich K; Reiter E; Gasser J; Bergmeister H; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2004 Jul; 50(7):2327-37. PubMed ID: 15248234
[TBL] [Abstract][Full Text] [Related]
18. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
[TBL] [Abstract][Full Text] [Related]
19. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
20. Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo.
Görtz B; Hayer S; Tuerck B; Zwerina J; Smolen JS; Schett G
Arthritis Res Ther; 2005; 7(5):R1140-7. PubMed ID: 16207331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
